Search Knowledge Base

3 results for "adverse-drug-reaction-reporting-systems"

Signal detection of ferric carboxymaltose-induced serious adverse events: disproportionality analysis of FAERS and VigiBase data and systematic review of case reports pubmed_article
Evidence Source 2025 PMID: 40402208
Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons pubmed_article
Evidence Source 2016 PMID: 27467204
The safety of herbal medicinal products derived from Echinacea species: a systematic review pubmed_article
Evidence Source 2005 PMID: 15853441

Evidence Search Results semantic · quality-ranked

Liver function monitoring: a prospective nested case-control study of Salvia miltiorrhiza polyphenol injection meta_analysis pubmed_article
Quality: 59 2020 PMID: 32103121 DOI: 10.1038/s41598-020-60608-z
Signal detection of ferric carboxymaltose-induced serious adverse events: disproportionality analysis of FAERS and VigiBase data and systematic review of case reports systematic_review pubmed_article
Quality: 50 2025 PMID: 40402208 DOI: 10.1007/s00228-025-03849-z
Challenging the dose-response-time data approach: Analysis of a complex system meta_analysis pubmed_article
Quality: 60 2019 PMID: 30453011 DOI: 10.1016/j.ejps.2018.11.015
Advances in drug discovery to assess cholinergic neurotransmission: a systematic review systematic_review pubmed_article
Quality: 44 2008 PMID: 18690892
Epinephrine and emergency medical services activation recommendations during acute allergic reactions in community settings: International consensus report. guideline guideline
Quality: 65 2026 PMID: 41386477 DOI: 10.1016/j.jaci.2025.11.008
[Expert consensus on amivantamab clinical application and adverse reaction management (2025 edition)]. guideline guideline
Quality: 65 2025 PMID: 41443730 DOI: 10.3760/cma.j.cn112152-20250718-00348
[Expert consensus on adverse reaction management of PAM pathway inhibitors in breast cancer (2026 edition)]. guideline guideline
Quality: 65 2026 PMID: 41688204 DOI: 10.3760/cma.j.cn112152-20251110-00558
Prevention and management of amivantamab-induced dermatologic toxicities: a European expert consensus and practical algorithm. guideline guideline
Quality: 65 2026 PMID: 41671631 DOI: 10.1016/j.lungcan.2026.108950
Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update. guideline guideline
Quality: 65 2024 PMID: 38402364 DOI: 10.1007/s12072-023-10633-7
International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML. guideline guideline
Quality: 65 2025 PMID: 40829117 DOI: 10.1182/bloodadvances.2025017011

View full evidence search →